Q2 EPS Estimate for Nurix Therapeutics Lifted by Analyst

Key Points

• HC Wainwright raised its Q2 2026 EPS estimate for Nurix to ($0.73) from ($0.74), maintained a Buy rating and a $32 price target, and projects FY2026 EPS of ($3.08).
• Nurix reported Q1 EPS of ($0.79), missing the ($0.76) consensus and posting revenue of $6.25M versus $14.25M expected, contributing to large negative margins while shares trade around $15.91.
• Institutional investors (Vanguard, Morgan Stanley, General Atlantic) materially increased positions even as insiders trimmed stakes; the analyst consensus remains a Moderate Buy with an average target of $30.46.

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - HC Wainwright raised their Q2 2026 earnings estimates for shares of Nurix Therapeutics in a report issued on Friday, April 10th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.73) per share for the quarter, up from their prior estimate of ($0.74). HC Wainwright currently has a "Buy" rating and a $32.00 price objective on the stock. The consensus estimate for Nurix Therapeutics' current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Nurix Therapeutics' Q3 2026 earnings at ($0.76) EPS, Q4 2026 earnings at ($0.79) EPS and FY2026 earnings at ($3.08) EPS.

Several other research analysts have also recently issued reports on the stock. BTIG Research restated a "buy" rating and issued a $30.00 target price on shares of Nurix Therapeutics in a report on Thursday, January 29th. Weiss Ratings restated a "sell (d-)" rating on shares of Nurix Therapeutics in a report on Thursday, January 22nd. Piper Sandler upped their target price on shares of Nurix Therapeutics from $32.00 to $35.00 and gave the company an "overweight" rating in a report on Thursday, January 29th. Morgan Stanley set a $36.00 target price on shares of Nurix Therapeutics and gave the company an "overweight" rating in a report on Thursday, January 8th. Finally, Needham & Company LLC restated a "buy" rating and issued a $26.00 target price on shares of Nurix Therapeutics in a report on Wednesday, April 8th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $30.46.

Nurix Therapeutics Trading Down 0.7%

Shares of NASDAQ:NRIX opened at $15.91 on Tuesday. Nurix Therapeutics has a 52 week low of $8.19 and a 52 week high of $22.50. The company's 50 day moving average is $15.66 and its two-hundred day moving average is $15.43. The company has a market cap of $1.65 billion, a PE ratio of -5.03 and a beta of 1.97.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 8th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.03). Nurix Therapeutics had a negative net margin of 411.37% and a negative return on equity of 64.21%. The firm had revenue of $6.25 million during the quarter, compared to analysts' expectations of $14.25 million.

Insiders Place Their Bets

In related news, CFO Houte Hans Van sold 3,661 shares of the stock in a transaction on Friday, January 30th. The shares were sold at an average price of $16.60, for a total transaction of $60,772.60. Following the completion of the sale, the chief financial officer owned 45,427 shares in the company, valued at $754,088.20. This represents a 7.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gwenn Hansen sold 4,895 shares of the stock in a transaction on Friday, January 30th. The stock was sold at an average price of $16.60, for a total transaction of $81,257.00. Following the sale, the insider owned 83,672 shares of the company's stock, valued at approximately $1,388,955.20. This represents a 5.53% decrease in their position. The disclosure for this sale is available in the SEC filing. 6.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Nurix Therapeutics

A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Nurix Therapeutics by 32.5% during the 4th quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company's stock worth $112,862,000 after buying an additional 1,460,736 shares during the last quarter. General Atlantic L.P. purchased a new position in Nurix Therapeutics during the 4th quarter worth $92,899,000. Morgan Stanley raised its position in Nurix Therapeutics by 115.9% during the 4th quarter. Morgan Stanley now owns 4,881,069 shares of the company's stock worth $92,594,000 after buying an additional 2,620,323 shares during the last quarter. Vestal Point Capital LP raised its position in Nurix Therapeutics by 35.0% during the 4th quarter. Vestal Point Capital LP now owns 4,690,000 shares of the company's stock worth $88,969,000 after buying an additional 1,215,000 shares during the last quarter. Finally, Baker BROS. Advisors LP raised its position in Nurix Therapeutics by 20.0% during the 4th quarter. Baker BROS. Advisors LP now owns 4,658,556 shares of the company's stock worth $88,373,000 after buying an additional 776,431 shares during the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company's pipeline includes multiple programs in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.